Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 23, 2020 08:30 ET | Source: Veru Inc.

Veru Receives Positive Input from FDA on Phase 3 Pivotal Trial to Evaluate VERU-111 in Metastatic Castration Resistant Prostate Cancer

MIAMI, July 23, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer,...
June 29, 2020 08:30 ET | Source: Veru Inc.

Veru Inc. Added to the Russell 2000 and 3000 Indices

MIAMI, June 29, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer,...
June 19, 2020 08:30 ET | Source: Veru Inc.

Veru Enrolls First Patient in Phase 2 Clinical Trial of Novel Drug, VERU-111, to Combat COVID-19

MIAMI, June 19, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer,...
May 26, 2020 08:30 ET | Source: Veru Inc.

Veru to Present at Jefferies Virtual Healthcare Conference on June 2nd

MIAMI, May 26, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer,...
May 13, 2020 06:30 ET | Source: Veru Inc.

Veru Reports Strong Fiscal 2020 Second Quarter Results as Net Revenues Increase 43%, Gross Profit Up 61%

--Strong Clinical Progress in Advanced Prostate Cancer: VERU-111 Demonstrates Safety and Evidence of Antitumor Activity with Durable PSA Declines and Tumor Regression in Phase 1b Study; Phase 2 Study...
May 12, 2020 12:00 ET | Source: Veru Inc.

Veru Secures FDA Agreement to Initiate Phase 2 Study of VERU-111, Novel Microtubule Depolymerization Drug to Combat COVID-19

--VERU-111’s Ability to Disrupt Microtubules has Potential for Dual Drug Action Against COVID-19: Treat SARS-CoV-2 Virus Infection and Reduce Inflammation Caused by Viral Infection-Induced Cytokine...
May 06, 2020 08:30 ET | Source: Veru Inc.

Veru to Report Fiscal 2020 Second-Quarter Financial Results, Host Conference Call on May 13th

MIAMI , May 06, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer,...
May 05, 2020 08:30 ET | Source: Veru Inc.

Veru Reports Positive Clinical Results from VERU-111 Phase 1b/2 Trial in Men with Metastatic Castration-Resistant Prostate Cancer, Advancing to Pivotal Phase 3 Clinical Program

--VERU-111 Safe and Well Tolerated at Daily Doses 63 mg and Lower; No Significant Neutropenia or Neurotoxicity Observed-- --Evidence of antitumor activity; durable PSA declines, objective...
February 26, 2020 08:30 ET | Source: Veru Inc.

Veru Initiates Phase 2 Clinical Trial of VERU-111, First-in-Class, Oral, Advanced Prostate Cancer Drug

--VERU-111 Targeting Men with Metastatic Castration Resistant Prostate Cancer Who Have Also Become Resistant to Abiraterone or Enzalutamide-- --Phase 2 Study Results Expected by Calendar Year...
February 12, 2020 06:30 ET | Source: Veru Inc.

Veru Continues Strong Positive Sales Momentum in Fiscal 2020 First Quarter; Net Revenues Increase 66%, Gross Profit Up 57%

--Completion of VERU-111 Phase 1b Clinical Trial and Initiation of Phase 2 Prostate Cancer Clinical Trial in Q2 FY 2020-- --Zuclomiphene Expected to Enter Pivotal Phase 3 Clinical Trial for Treating...